SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. -- ICUI

NEW YORK, April 19, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ICU Medical, Inc. ("ICU Medical" or the "Company") (NASDAQ: ICUI).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether ICU Medical and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On April 18, 2017, post-market, ICU Medical disclosed that the Company had receive a subpoena from the U.S. Department of Justice requesting "documents regarding the manufacturing, selling, pricing and shortages of intravenous solutions, including saline" that the Company gained when it acquired the infusion systems business of Pfizer Inc.'s Hospira unit. 

On this news, ICU Medical's share price has fallen as much as $1.55, or 1.06%, during intraday trading on April 19, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-icu-medical-inc----icui-300441979.html

SOURCE Pomerantz LLP